+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
MALE
ID07723248

Phase 3 Study Comparing Rinzimetostat Plus Darolutamide Versus Standard Treatments in Men With Metastatic Castration Resistant Prostate Cancer Previously Treated With Abiraterone Acetate

Led by ORIC Pharmaceuticals · Updated on 2026-11-03

600

Participants Needed

15

Research Sites

130 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the combination of rinzimetostat with darolutamide compared to physicians choice of control treatmentseither androgen receptor pathway inhibitors darolutamide or enzalutamide or docetaxel chemotherapyin patients with metastatic castration resistant prostate cancer mCRPC who have previously been treated with abiraterone acetate. This global, randomized, open-label phase 3 study aims to determine if the combination improves radiographic progression free survival. Participants are assigned to one of two groups the investigational arm receiving rinzimetostat at 400 mg once daily plus darolutamide at 600 mg twice daily, or the control arm receiving physicians choice of either darolutamide, enzalutamide, or docetaxel administered intravenously every 21 days for up to 10 cycles. The study treatment period extends up to approximately two years, with additional long-term follow-up for various outcomes up to five years. During the study, participants undergo regular assessments including imaging scans reviewed centrally to measure disease progression, blood tests for prostate specific antigen PSA levels, and patient-reported questionnaires on pain and quality of life. Researchers monitor overall survival, response rates, side effects, and pharmacokinetics. The study continues safety and efficacy follow-up for several years, with total participation lasting up to around four to five years depending on individual outcomes.

CONDITIONS

Brief Title

A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)

Research Team

O

ORIC Clinical Call Center

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here